Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated:  11/26/2015
Clinical Research Facility
mi
from
Durham, NC
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated: 11/26/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated:  11/26/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated: 11/26/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated:  11/26/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis
Status: Enrolling
Updated: 11/26/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Status: Enrolling
Updated:  11/30/2015
Washington DC VA Medical Center
mi
from
Washington,
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Status: Enrolling
Updated: 11/30/2015
Washington DC VA Medical Center
mi
from
Washington,
Click here to add this to my saved trials
TOPIC Trial for COPD
A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)
Status: Enrolling
Updated:  11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
TOPIC Trial for COPD
A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)
Status: Enrolling
Updated: 11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea
The Role of Tonsillectomy in Adults With Marked Tonsillar Hypertrophy and Obstructive Sleep Apnea
Status: Enrolling
Updated:  11/30/2015
Keck Hospital of USC
mi
from
Los Angeles, CA
Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea
The Role of Tonsillectomy in Adults With Marked Tonsillar Hypertrophy and Obstructive Sleep Apnea
Status: Enrolling
Updated: 11/30/2015
Keck Hospital of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated:  11/30/2015
University of Colorado Health Sciences Center
mi
from
Denver, CO
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated: 11/30/2015
University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated:  11/30/2015
Emory University
mi
from
Atlanta, GA
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated: 11/30/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated:  11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Status: Enrolling
Updated: 11/30/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
Puget Sound Veterans Administration Health Care System
mi
from
Seattle, WA
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
Puget Sound Veterans Administration Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
Univ of Washington
mi
from
Seattle, WA
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Microaspiration in Pulmonary Fibrosis
The Role of Microaspiration in Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  12/1/2015
University of California at San Francisco
mi
from
San Francisco, CA
Microaspiration in Pulmonary Fibrosis
The Role of Microaspiration in Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 12/1/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Birmingham, AL
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Palo Alto, CA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Denver, CO
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Hartford, CT
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Tampa, FL
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Atlanta, GA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Chicago, IL
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Iowa City, IA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Lexington, KY
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Baltimore, MD
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Boston, MA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Detroit, MI
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
St. Louis, MO
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Omaha, NE
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
New York, NY
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Syracuse, NY
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Valhalla, NY
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Charleston, SC
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Dallas, TX
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Houston, TX
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Richmond, VA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Morgantown, WV
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Madison, WI
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
mi
from
Leuven,
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
mi
from
Leuven,
Click here to add this to my saved trials
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Birmingham, AL
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials